Liraglutide vs Tirzepatide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Liraglutide
Liraglutide is a once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analog approved for both type 2 diabetes (Victoza, 1.8mg) and chronic weight management (Saxenda, 3mg). It was the foundational GLP-1 agonist that established the class's cardiovascular benefits and set the stage for semaglutide and tirzepatide.
Full profileTirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), it produces greater weight loss than any approved GLP-1 monotherapy in clinical trials.
Full profile| Liraglutide | Tirzepatide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | NN2211, Victoza, Saxenda | LY3298176, Mounjaro, Zepbound |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 0.6mg–3.0mg mg, Once daily subcutaneous injection | 2.5mg–15mg mg, Once weekly subcutaneous injection |
| Administration | Subcutaneous injection (abdomen, thigh, or upper arm) | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Key side effects | Nausea (most common, especially during initiation), Vomiting, Diarrhea, Decreased appetite | Nausea (most common, especially during titration), Vomiting, Diarrhea, Constipation |
| Cited sources | 2 references | 4 references |
Key differences
- Frequency: Liraglutide is typically Once daily subcutaneous injection; Tirzepatide is Once weekly subcutaneous injection.
- Research depth: this profile cites 2 sources for Liraglutide vs 4 for Tirzepatide.
How each works
Liraglutide
The LEADER trial (N=9340) demonstrated significant reduction in major adverse cardiovascular events (MACE) in high-risk T2D patients — the first cardiovascular outcomes trial for a GLP-1 agonist. The SCALE trials showed 5–8% mean weight loss at 3mg/day vs placebo. While superseded by semaglutide and tirzepatide in weight loss efficacy, liraglutide has the longest safety record in the class (approved 2010) and daily dosing allows finer tolerability titration.
Tirzepatide
The SURMOUNT-1 trial (N=2539) demonstrated up to 22.5% mean body weight reduction over 72 weeks at the 15mg dose — the highest efficacy ever recorded for a pharmaceutical weight loss agent at time of publication. The dual mechanism leverages GIP's potentiation of insulin secretion and adipose tissue effects alongside GLP-1's appetite suppression and gastric motility slowing. Head-to-head data (SURMOUNT-5) shows tirzepatide outperforms semaglutide 2.4mg for weight loss.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.